<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37857371</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-4804</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>21</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>09</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Structure-Based Lead Optimization of Enterovirus D68 2A Protease Inhibitors.</ArticleTitle><Pagination><StartPage>14544</StartPage><EndPage>14563</EndPage><MedlinePgn>14544-14563</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.3c00995</ELocationID><Abstract><AbstractText>Enterovirus D68 (EV-D68) virus is a nonpolio enterovirus that typically causes respiratory illness and, in severe cases, can lead to paralysis and death in children. There is currently no vaccine or antiviral for EV-D68. We previously discovered the viral 2A protease (2A<sup>pro</sup>) as a viable antiviral drug target and identified telaprevir as a 2A<sup>pro</sup> inhibitor. 2A<sup>pro</sup> is a viral cysteine protease that cleaves the viral VP1-2A polyprotein junction. In this study, we report the X-ray crystal structures of EV-D68 2A<sup>pro</sup>, wild-type, and the C107A mutant and the structure-based lead optimization of telaprevir. Guided by the X-ray crystal structure, we predicted the binding pose of telaprevir in 2A<sup>pro</sup> using molecular dynamics simulations. We then utilized this model to inform structure-based optimization of the telaprevir's reactive warhead and P1-P4 substitutions. These efforts led to the discovery of 2A<sup>pro</sup> inhibitors with improved antiviral activity than telaprevir. These compounds represent promising lead compounds for further development as EV-D68 antivirals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Molecular Sciences and Biodesign Center for Applied Structural Discovery, Biodesign Institute, Arizona State University, Tempe, Arizona 85287, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jadhav</LastName><ForeName>Prakash</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambrinidis</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2820-9338</Identifier><AffiliationInfo><Affiliation>Laboratory of Medicinal Chemistry, Division of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cancer Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cancer Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Haozhou</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolocouris</LastName><ForeName>Antonios</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6110-1903</Identifier><AffiliationInfo><Affiliation>Laboratory of Medicinal Chemistry, Division of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Cancer Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4845-4621</Identifier><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI147325</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI157046</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI179926</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="Y">Enterovirus D, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. Jun Wang is an inventor of a filed patent claiming the use of <b>Jun11762</b> and related compounds as potential EV-D68 antiviral drugs.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>20</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>19</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37857371</ArticleId><ArticleId IdType="mid">NIHMS2023373</ArticleId><ArticleId IdType="pmc">PMC11457037</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.3c00995</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sun J; Hu XY; Yu XF, Current Understanding of Human Enterovirus D68. Viruses 2019, 11, 490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6631698</ArticleId><ArticleId IdType="pubmed">31146373</ArticleId></ArticleIdList></Reference><Reference><Citation>Schieble JH; Fox VL; Lennette EH, A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol 1967, 85, 297–310.</Citation><ArticleIdList><ArticleId IdType="pubmed">4960233</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley CM; Watson JT; Nix WA; Curns AT; Rogers SL; Brown BA; Conover C; Dominguez SR; Feikin DR; Gray S, et al., Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation. Lancet Respir Med 2015, 3, 879–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5693332</ArticleId><ArticleId IdType="pubmed">26482320</ArticleId></ArticleIdList></Reference><Reference><Citation>Poelman R; Schuffenecker I; Van Leer-Buter C; Josset L; Niesters HG; Lina B; group E.-E. E.-D. s., European surveillance for enterovirus D68 during the emerging North-American outbreak in 2014. J Clin Virol 2015, 71, 1–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26364237</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste MS; Maher K; Schnurr D; Flemister MR; Lovchik JC; Peters H; Sessions W; Kirk C; Chatterjee N; Fuller S, et al., Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J Gen Virol 2004, 85, 2577–2584.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302951</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K; Asturias EJ; Hixon AM; Van Leer-Buter C; Niesters HGM; Tyler KL; Abzug MJ; Dominguez SR, Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality. Lancet Infect Dis 2018, 18, e239–e247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778404</ArticleId><ArticleId IdType="pubmed">29482893</ArticleId></ArticleIdList></Reference><Reference><Citation>Opanda SM; Wamunyokoli F; Khamadi S; Coldren R; Bulimo WD, Genetic diversity of human enterovirus 68 strains isolated in Kenya using the hypervariable 3’-end of VP1 gene. PLoS One 2014, 9, e102866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108357</ArticleId><ArticleId IdType="pubmed">25054861</ArticleId></ArticleIdList></Reference><Reference><Citation>Agol VI, [Various problems in the molecular biology of picornaviruses]. Mol Biol (Mosk) 1977, 11, 1213–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">221803</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R; Ma C; Zhang J; Hu Y; Diesing JM; Marty MT; Wang J, Validating Enterovirus D68–2A(pro) as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68–2A(pro) Inhibitor. J Virol 2019, 93, e02221–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6430540</ArticleId><ArticleId IdType="pubmed">30674624</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J; George S; Kusov Y; Perbandt M; Anemuller S; Mesters JR; Norder H; Coutard B; Lacroix C; Leyssen P, et al., 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J Virol 2013, 87, 4339–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624371</ArticleId><ArticleId IdType="pubmed">23388726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y; Musharrafieh R; Zheng M; Wang J, Enterovirus D68 Antivirals: Past, Present, and Future. ACS Infect Dis 2020, 6, 1572–1586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055446</ArticleId><ArticleId IdType="pubmed">32352280</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J; Thibaut HJ; Strating J; van Kuppeveld FJM, The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol 2018, 16, 368–381.</Citation><ArticleIdList><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q; Yameen M; Liu W; Gao Z; Li Y; Peng X; Cai Y; Wu C; Zheng Q; Li J, et al., Conformational plasticity of the 2A proteinase from enterovirus 71. J Virol 2013, 87, 7348–56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700279</ArticleId><ArticleId IdType="pubmed">23616646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y, et al., Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res 2020, 30, 678–692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7294525</ArticleId><ArticleId IdType="pubmed">32541865</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan B; Joyce R; Tan H; Hu Y; Wang J, SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies. Acc. Chem. Res 2023, 56, 157–168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9843634</ArticleId><ArticleId IdType="pubmed">36580641</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR; Allerton CMN; Anderson AS; Aschenbrenner L; Avery M; Berritt S; Boras B; Cardin RD; Carlo A; Coffman KJ, et al., An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 2021, 374, 1586–1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce RP; Hu VW; Wang J, The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med Chem Res 2022, 31, 1637–1646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9425786</ArticleId><ArticleId IdType="pubmed">36060104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J, Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses. ACS Infect Dis 2021, 7, 586–597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944397</ArticleId><ArticleId IdType="pubmed">33645977</ArticleId></ArticleIdList></Reference><Reference><Citation>Elrick MJ; Pekosz A; Duggal P, Enterovirus D68 molecular and cellular biology and pathogenesis. J Biol Chem 2021, 296, 100317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7949111</ArticleId><ArticleId IdType="pubmed">33484714</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DM; Hixon AM; Oldfield LM; Zhang Y; Novotny M; Wang W; Das SR; Shabman RS; Tyler KL; Scheuermann RH, Contemporary Circulating Enterovirus D68 Strains Have Acquired the Capacity for Viral Entry and Replication in Human Neuronal Cells. mBio 2018, 9, e01954–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6191546</ArticleId><ArticleId IdType="pubmed">30327438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y; Cao J; Zhang S; Lee AJ; Sun G; Larsen CN; Zhao H; Gu Z; He S; Klem EB, et al., Genetic changes found in a distinct clade of Enterovirus D68 associated with paralysis during the 2014 outbreak. Virus Evol 2016, 2, vew015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5426007</ArticleId><ArticleId IdType="pubmed">28512577</ArticleId></ArticleIdList></Reference><Reference><Citation>Morens DM; Folkers GK; Fauci AS, Acute Flaccid Myelitis: Something Old and Something New. mBio 2019, 10, e00521–19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6445942</ArticleId><ArticleId IdType="pubmed">30940708</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy OC; Pardo CA, Acute Flaccid Myelitis: A Clinical Review. Semin Neurol 2020, 40, 211–218.</Citation><ArticleIdList><ArticleId IdType="pubmed">32143233</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyda A; Stelzer-Braid S; Adam D; Chughtai AA; MacIntyre CR, The association between acute flaccid myelitis (AFM) and Enterovirus D68 (EV-D68) - what is the evidence for causation? Euro Surveill 2018, 23, 16–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792700</ArticleId><ArticleId IdType="pubmed">29386095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixon AM; Frost J; Rudy MJ; Messacar K; Clarke P; Tyler KL, Understanding Enterovirus D68-Induced Neurologic Disease: A Basic Science Review. Viruses 2019, 11, 821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783995</ArticleId><ArticleId IdType="pubmed">31487952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurst BL; Evans WJ; Smee DF; Van Wettere AJ; Tarbet EB, Evaluation of antiviral therapies in respiratory and neurological disease models of Enterovirus D68 infection in mice. Virology 2019, 526, 146–154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309259</ArticleId><ArticleId IdType="pubmed">30390563</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost J; Rudy MJ; Leser JS; Tan H; Hu Y; Wang J; Clarke P; Tyler KL, Telaprevir Treatment Reduces Paralysis in a Mouse Model of Enterovirus D68 Acute Flaccid Myelitis. J. Virol 2023, 97, e0015623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10231134</ArticleId><ArticleId IdType="pubmed">37154751</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthew AN; Leidner F; Lockbaum GJ; Henes M; Zephyr J; Hou S; Rao DN; Timm J; Rusere LN; Ragland DA, et al., Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. Chem Rev 2021, 121, 3238–3270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126998</ArticleId><ArticleId IdType="pubmed">33410674</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R; Ma C; Wang J, Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers. Antiviral Res 2018, 153, 10–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5891360</ArticleId><ArticleId IdType="pubmed">29518414</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch W, XDS. Acta Crystallogr D Biol Crystallogr 2010, 66, 125–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815665</ArticleId><ArticleId IdType="pubmed">20124692</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD; Afonine PV; Bunkóczi G; Chen VB; Davis IW; Echols N; Headd JJ; Hung LW; Kapral GJ; Grosse-Kunstleve RW, et al., PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010, 66, 213–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Krissinel E; Uski V; Lebedev A; Winn M; Ballard C, Distributed computing for macromolecular crystallography. Acta Crystallogr D Struct Biol 2018, 74, 143–151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5947778</ArticleId><ArticleId IdType="pubmed">29533240</ArticleId></ArticleIdList></Reference><Reference><Citation>Smart OS; Womack TO; Flensburg C; Keller P; Paciorek W; Sharff A; Vonrhein C; Bricogne G, Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr D Biol Crystallogr 2012, 68, 368–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322596</ArticleId><ArticleId IdType="pubmed">22505257</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB; Davis IW; Richardson DC, KING (Kinemage, Next Generation): a versatile interactive molecular and scientific visualization program. Protein Sci 2009, 18, 2403–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788294</ArticleId><ArticleId IdType="pubmed">19768809</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady SD; Wang J; Wu Y; DeGrado WF; Hong M, Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy. J Am Chem Soc 2011, 133, 4274–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078525</ArticleId><ArticleId IdType="pubmed">21381693</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan B; Sacco M; Tan H; Li K; Joyce R; Zhang X; Chen Y; Wang J, Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors. Eur J Med Chem 2023, 259, 115667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10529912</ArticleId><ArticleId IdType="pubmed">37482021</ArticleId></ArticleIdList></Reference><Reference><Citation>Halgren TA, MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J Comput Chem 1999, 20, 730–748.</Citation><ArticleIdList><ArticleId IdType="pubmed">34376036</ArticleId></ArticleIdList></Reference><Reference><Citation>Halgren TA, Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 1996, 17, 490–519.</Citation></Reference><Reference><Citation>Jorgensen WL; Maxwell DS; TiradoRives J, Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996, 118, 11225–11236.</Citation></Reference><Reference><Citation>Kaminski GA; Friesner RA; Tirado-Rives J; Jorgensen WL, Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 2001, 105, 6474–6487.</Citation></Reference><Reference><Citation>Friesner RA; Murphy RB; Repasky MP; Frye LL; Greenwood JR; Halgren TA; Sanschagrin PC; Mainz DT, Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006, 49, 6177–96.</Citation><ArticleIdList><ArticleId IdType="pubmed">17034125</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF; Goddard TD; Huang CC; Couch GS; Greenblatt DM; Meng EC; Ferrin TE, UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004, 25, 1605–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen WL; Chandrasekhar J; Madura JD; Impey RW; Klein ML, Comparison of Simple Potential Functions for Simulating Liquid Water. J Chem Phys 1983, 79, 926–935.</Citation></Reference><Reference><Citation>Darden T; York D; Pedersen L, Particle Mesh Ewald - an N.Log(N) Method for Ewald Sums in Large Systems. J Chem Phys 1993, 98, 10089–10092.</Citation></Reference><Reference><Citation>Essmann U; Perera L; Berkowitz ML; Darden T; Lee H; Pedersen LG, A Smooth Particle Mesh Ewald Method. J Chem Phys 1995, 103, 8577–8593.</Citation></Reference><Reference><Citation>Izaguirre JA; Catarello DP; Wozniak JM; Skeel RD, Langevin stabilization of molecular dynamics. J Chem Phys 2001, 114, 2090–2098.</Citation></Reference><Reference><Citation>Feller SE; Zhang YH; Pastor RW; Brooks BR, Constant-Pressure Molecular-Dynamics Simulation - the Langevin Piston Method. J Chem Phys 1995, 103, 4613–4621.</Citation></Reference><Reference><Citation>Humphreys DD; Friesner RA; Berne BJ, A Multiple-Time-Step Molecular-Dynamics Algorithm for Macromolecules. J Phys Chem 1994, 98, 6885–6892.</Citation></Reference><Reference><Citation>Isgro TP, C. J; Sotomayor M; Villa E VMD NAMD Tutorial. VMD Tutor 2009.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>